• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [18753 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2007     HAYES, Inc. Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010     HAYES, Inc. Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2003     National Institute for Clinical Excellence (NICE) Transurethral radiofrequency needle ablation of the prostate
2011     HAYES, Inc. Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2016     NIHR Health Technology Assessment programme TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2004     HAYES, Inc. Trastuzumab (Herceptin (R)) for breast cancer
2007     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for advanced gastric cancer
2007     HAYES, Inc. Trastuzumab (Herceptin) for early breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2010     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2001     The Swedish Council on Health Technology Assessment (SBU) Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2007     HAYES, Inc. Trastuzumab (Herceptin) for metastatic cancer
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2006     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2003     ECRI Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2005     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2013     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Trastuzumab for breast cancer treatment
2006     Quality Improvement Scotland (NHS QIS ) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2006     National Institute for Health and Clinical Excellence (NICE) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2010     National Institute for Health and Clinical Excellence (NICE) Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
2009     NIHR Health Technology Assessment programme Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab SC (Herceptin SC) for breast cancer, early or metastatic, HER2 positive - monotherapy or combination therapy, including neo-adjuvant and adjuvant use
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab-DM1 (Herceptin-DM1) for breast cancer, locally advanced or metastatic, HER2 positive - second or third line
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Trauma release exercises for the treatment of mental health issues: clinical effectiveness, safety and guidelines
2011     Agency for Healthcare Research and Quality (AHRQ) Traumatic brain injury and depression.
2016     The Swedish Council on Health Technology Assessment (SBU) Traumatic shaking – The role of the triad in medical investigations of suspected traumatic shaking
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Travoprost (Travatan®)
2000     The Swedish Council on Health Technology Assessment (SBU) Treating asthma and COPD - a systematic review
1999     University of York Treating head lice and scabies
2001     The Swedish Council on Health Technology Assessment (SBU) Treating influenza by medication - zanamivir - early assessment briefs (ALERT)
2003     University of York Treating nocturnal enuresis in children
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treating osteoporosis with teriparatide: many unknowns?
2002     Norwegian Knowledge Centre for the Health Services (NOKC) Treating prostate cancer with brachytherapy
2011     Health Council of the Netherlands Gezondheidsraad (GR) Treating the effect of child abuse
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment and rehabilitation of people with fibromyalgia
2010     Institute of Health Economics (IHE) Treatment for convicted adult male sex offenders
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for depression after unsatisfactory response to SSRIs
2008     NIHR Health Technology Assessment programme Treatment for fibroids: Uterine Artery Embolisation (UAE) or hysterectomy (HOPEFUL) - Primary Research (e.g. trial)
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for hepatitis C virus infection in adults
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for restless legs syndrome
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies
2022     NIHR Health Technology Assessment programme Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2001     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of age related macular degeneration
2001     The Swedish Council on Health Technology Assessment (SBU) Treatment of alcohol and drug abuse - an evidence-based review
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors: a review of the clinical evidence
2005     The Swedish Council on Health Technology Assessment (SBU) Treatment of anxiety disorders: a systematic review
2013     Agency for Healthcare Research and Quality (AHRQ) Treatment of atrial fibrillation
1999     Agency for Healthcare Research and Quality (AHRQ) Treatment of attention-deficit/hyperactivity disorder
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of autism
2022     NIHR Health Technology Assessment programme Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): a randomised placebo-controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
1995     Australian Health Technology Advisory Committee (AHTAC) Treatment of benign prostatic hyperplasia in Australia - some economic considerations
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of carpal tunnel syndrome - primary research
2015     NIHR Health Technology Assessment programme Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis
2003     Agency for Healthcare Research and Quality (AHRQ) Treatment of coexisting cataract and glaucoma
2009     Agency for Healthcare Research and Quality (AHRQ) Treatment of common hip fractures
1997     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of constipation in children with biofeedback-training - primary research
1999     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of cranio-mandibular dysfunction - primary research
2001     Agency for Healthcare Research and Quality (AHRQ) Treatment of degenerative lumbar spinal stenosis - Volume 1. Evidence report; Volume 2. Evidence tables and bibliography
2004     The Swedish Council on Health Technology Assessment (SBU) Treatment of depression
1999     Agency for Healthcare Research and Quality (AHRQ) Treatment of depression - newer pharmacotherapies
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of diastasis recti
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of diffuse systemic sclerosis with photopheresis - primary research
2002     NIHR Health Technology Assessment programme Treatment of established osteoporosis: a systematic review and cost-utility analysis
2019     NIHR Health Technology Assessment programme Treatment of first-time traumatic anterior shoulder dislocation UK.TASH-D Study
2007     Haute Autorite de sante (HAS) Treatment of hearing loss by cochlear implantation or auditory brain stem implantation
2005     Medical Services Advisory Committee (MSAC) Treatment of heart failure by permanent tri-chamber synchronisation (#1042)
2011     The Swedish Council on Health Technology Assessment (SBU) Treatment of hemophilia A and B and von willebrand disease
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of hydromyelia in adults: a review of clinical effectiveness and guidelines
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of hyperemesis (severe nausea during pregnancy)
2009     Norwegian Knowledge Centre for the Health Services (NOKC) Treatment of infantile colic
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treatment of inoperable advanced non-small-cell lung cancer: regimens with or without taxane
2010     The Swedish Council on Health Technology Assessment (SBU) Treatment of insomnia in adults
2004     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of leg varices
2001     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of localised prostate cancer
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of low back pain - primary research
2004     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of lower limbs arteriopathy
2001     Norwegian Knowledge Centre for the Health Services (NOKC) Treatment of lumbar disc herniation
2007     Haute Autorite de sante (HAS) Treatment of multiple missing teeth in children with rare diseases by implant placement
2000     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of neck complaints - primary research
1995     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of neurogenic bladder dysfunction - primary research
2020     Swiss Federal Office of Public Health (FOPH) Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitor therapy
2015     Agency for Healthcare Research and Quality (AHRQ) Treatment of nonmetastatic muscle-invasive bladder cancer
2005     Institute for Clinical Systems Improvement (ICSI) Treatment of obesity in children and adolescents
1995     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treatment of obstructive sleep apnea: an overview - nonsystematic review
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of older patients with acute myeloid leukemia by hematopoietic growth factor combined with chemotherapy- primary research
2017     Agency for Healthcare Research and Quality (AHRQ) Treatment of osteoarthritis of the knee: an update review
2009     Agency for Healthcare Research and Quality (AHRQ) Treatment of overactive bladder in women
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of patients with multiple sclerosis: a review of guidelines
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of periodontal disease in patients with diabetes: a review of clinical and cost-effectiveness
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of port wine stains with the pulsed dye laser: younger and better? - primary research
1998     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of postoperative pain - primary research